We’d not come across Avinger, Inc., designer of therapeutic devices incorporating intravascular imaging and pioneer of the lumivascular approach to treating vascular disease. Now the company has announced that it has received CE Mark approval for Pantheris, a system that combines directional atherectomy capabilities with real-time intravascular visualization to remove plaque from blocked arteries.
Founded in 2007, Avinger seeks to radically change the treatment of vascular disease through the development of new technology and a new approach which it has tagged “lumivascular” (lumi = light, vascular = artery). Lumivascular procedures use an interventional catheter system that incorporates light-based, radiation-free, intravascular imaging technology within the actual therapeutic device. This provides physicians with live, real-time, video-rate images of the inside of an artery during treatment, offering a variety of benefits for patients, physicians and hospitals.
The company’s newly CE marked offering, Pantheris is designed to remove blockages in peripheral arteries while avoiding the disruption of normal arterial wall structures.
The first commercial Pantheris cases in Europe are to be performed by Arne Schwindt, MD of St. Franziskus Hospital in Muenster, Germany. Dr. Schwindt is also a co-principal investigator of the Avinger’s US IDE trial, VISION. VISION is a multi-center, non-randomized global clinical study designed to evaluate the safety and efficacy of Pantheris.
“I’ve always been an advocate of using atherectomy as a minimally invasive way to treat patients with PAD,” said Dr. Schwindt. “And now with Pantheris, I won’t have to play the guessing game to decide what part of the artery needs to be treated. I’ll be able to see what I need to cut, and what should be left alone. The benefits of this advantage for my patients could be dramatic.”
“This is a major milestone for Avinger, and I couldn’t be more pleased with the progress we’ve made by getting Pantheris to market in Europe,” said founder and Chief Executive Officer John B. Simpson PhD, MD. “Providing physicians with a tool to see the difference between the healthy artery wall and the disease itself while treating the vessel in real time – this is what I’ve been working towards for my entire career.”
Source: Avinger, Inc.